JP2010509315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509315A5 JP2010509315A5 JP2009535878A JP2009535878A JP2010509315A5 JP 2010509315 A5 JP2010509315 A5 JP 2010509315A5 JP 2009535878 A JP2009535878 A JP 2009535878A JP 2009535878 A JP2009535878 A JP 2009535878A JP 2010509315 A5 JP2010509315 A5 JP 2010509315A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- targeting agent
- antibody
- compound according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 230000008685 targeting Effects 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 4
- -1 dichlorobenzoyl Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 125000006333 difluoro benzoyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 108010071579 antibody aldolase Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 0 CC(CC(C*)O)NC Chemical compound CC(CC(C*)O)NC 0.000 description 3
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86536006P | 2006-11-10 | 2006-11-10 | |
| US60/865,360 | 2006-11-10 | ||
| US93983007P | 2007-05-23 | 2007-05-23 | |
| US60/939,830 | 2007-05-23 | ||
| US94532907P | 2007-06-20 | 2007-06-20 | |
| US60/945,329 | 2007-06-20 | ||
| PCT/IE2007/000110 WO2008056346A2 (en) | 2006-11-10 | 2007-11-12 | Anti-angiogenic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011283619A Division JP2012121886A (ja) | 2006-11-10 | 2011-12-26 | 抗血管形成化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509315A JP2010509315A (ja) | 2010-03-25 |
| JP2010509315A5 true JP2010509315A5 (enExample) | 2010-12-16 |
| JP4897050B2 JP4897050B2 (ja) | 2012-03-14 |
Family
ID=39364902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535878A Expired - Fee Related JP4897050B2 (ja) | 2006-11-10 | 2007-11-12 | 抗血管形成化合物 |
| JP2011283619A Ceased JP2012121886A (ja) | 2006-11-10 | 2011-12-26 | 抗血管形成化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011283619A Ceased JP2012121886A (ja) | 2006-11-10 | 2011-12-26 | 抗血管形成化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8288349B2 (enExample) |
| EP (2) | EP2089425B1 (enExample) |
| JP (2) | JP4897050B2 (enExample) |
| KR (2) | KR20120043028A (enExample) |
| CN (1) | CN101611053B (enExample) |
| AT (1) | ATE520712T1 (enExample) |
| AU (1) | AU2007318912B2 (enExample) |
| BR (1) | BRPI0718591A2 (enExample) |
| CA (1) | CA2669207A1 (enExample) |
| DK (1) | DK2089425T3 (enExample) |
| IL (1) | IL198581A (enExample) |
| MX (1) | MX2009005045A (enExample) |
| MY (1) | MY146985A (enExample) |
| NO (1) | NO20092203L (enExample) |
| NZ (1) | NZ576751A (enExample) |
| PL (1) | PL2089425T3 (enExample) |
| PT (1) | PT2089425E (enExample) |
| WO (1) | WO2008056346A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120043028A (ko) * | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| WO2010036930A1 (en) * | 2008-09-26 | 2010-04-01 | Javad Parvizi | Methods and kits for detecting joint infection |
| EP2593142B8 (en) * | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| RU2013118441A (ru) | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| JP6069312B2 (ja) | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
| CA2860109C (en) * | 2011-12-20 | 2016-08-09 | Javier Magano | Improved processes for preparing peptide conjugates and linkers |
| TW201341401A (zh) * | 2012-01-09 | 2013-10-16 | Covx Technologies Ireland Ltd | 突變抗體及其共軛 |
| JP6219923B2 (ja) | 2012-03-28 | 2017-10-25 | アムジェン インコーポレイテッド | Ｄｒ５受容体アゴニストの組み合わせ |
| EP3007717B1 (en) | 2013-06-12 | 2018-08-29 | Pharis Biotec GmbH | Peptides with antagonistic activities against natural cxcr4 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| BR112016007622A2 (pt) | 2013-10-15 | 2018-01-23 | Seattle Genetics, Inc. | composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| SG11201804268RA (en) | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| BR112018069273A2 (pt) | 2016-03-25 | 2019-01-22 | Seattle Genetics Inc | métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco |
| MX2019008449A (es) | 2017-02-08 | 2019-09-09 | Bristol Myers Squibb Co | Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos. |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| EP3617235A4 (en) | 2017-04-28 | 2020-12-16 | Ajinomoto Co., Inc. | COMPOUND CONTAINING A SUBSTANCE HAVING AFFINITY FOR A SOLUBLE PROTEIN, CLIVABLE FRACTION, AND REACTIVE GROUP, OR SALT OF THE SAME |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5216132A (en) | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| DE69126871T2 (de) | 1990-04-06 | 1998-03-12 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| AU1190101A (en) | 1999-09-27 | 2001-04-30 | Regents Of The University Of California, The | Engineering antibodies that bind irreversibly |
| US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US20030045477A1 (en) | 2001-07-26 | 2003-03-06 | Fortuna Haviv | Peptides having antiangiogenic activity |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| KR20040058229A (ko) * | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| US6737524B2 (en) * | 2002-03-25 | 2004-05-18 | Paul K. Smith | Activated polyethylene glycol compounds |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| WO2006036834A2 (en) * | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| KR20120043028A (ko) * | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
-
2007
- 2007-11-12 KR KR1020127005049A patent/KR20120043028A/ko not_active Ceased
- 2007-11-12 PL PL07827123T patent/PL2089425T3/pl unknown
- 2007-11-12 EP EP07827123A patent/EP2089425B1/en not_active Not-in-force
- 2007-11-12 EP EP20110170480 patent/EP2368908A3/en not_active Withdrawn
- 2007-11-12 NZ NZ576751A patent/NZ576751A/en not_active IP Right Cessation
- 2007-11-12 AU AU2007318912A patent/AU2007318912B2/en not_active Ceased
- 2007-11-12 MX MX2009005045A patent/MX2009005045A/es active IP Right Grant
- 2007-11-12 CN CN200780049649.0A patent/CN101611053B/zh not_active Expired - Fee Related
- 2007-11-12 PT PT07827123T patent/PT2089425E/pt unknown
- 2007-11-12 CA CA002669207A patent/CA2669207A1/en not_active Abandoned
- 2007-11-12 US US11/938,766 patent/US8288349B2/en not_active Expired - Fee Related
- 2007-11-12 KR KR1020097011924A patent/KR101309948B1/ko not_active Expired - Fee Related
- 2007-11-12 AT AT07827123T patent/ATE520712T1/de active
- 2007-11-12 WO PCT/IE2007/000110 patent/WO2008056346A2/en not_active Ceased
- 2007-11-12 MY MYPI20091889A patent/MY146985A/en unknown
- 2007-11-12 BR BRPI0718591-0A patent/BRPI0718591A2/pt not_active IP Right Cessation
- 2007-11-12 JP JP2009535878A patent/JP4897050B2/ja not_active Expired - Fee Related
- 2007-11-12 DK DK07827123.6T patent/DK2089425T3/da active
-
2009
- 2009-05-05 IL IL198581A patent/IL198581A/en active IP Right Grant
- 2009-06-08 NO NO20092203A patent/NO20092203L/no not_active Application Discontinuation
-
2011
- 2011-12-26 JP JP2011283619A patent/JP2012121886A/ja not_active Ceased
-
2012
- 2012-08-13 US US13/584,721 patent/US8912148B2/en not_active Expired - Fee Related
-
2014
- 2014-10-31 US US14/530,444 patent/US20150057431A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509315A5 (enExample) | ||
| WO2008056346B1 (en) | Anti-angiogenic compounds | |
| JP7403507B2 (ja) | 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート | |
| KR102209395B1 (ko) | 새로운 약물-단백질 접합체 | |
| JP2010514835A5 (enExample) | ||
| CN102123737B (zh) | 用于生物活性化合物施用的轭合物 | |
| CN112601522B (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| JP2019501141A (ja) | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート | |
| US20140079722A1 (en) | Extracellular targeted drug conjugates | |
| JP2008515889A5 (enExample) | ||
| AU2016354009B2 (en) | Anti-CD22 antibody-maytansine conjugates and methods of use thereof | |
| IL294321A (en) | Site specific antibody-drug conjugates with peptide-containing linkers | |
| KR20240083174A (ko) | 종양 관련 칼슘 신호 전달 인자 2 (tacstd2) 항체-메이탄신 접합체 및 이의 사용 방법 | |
| JP2023509760A (ja) | Ａｌｋ５阻害剤複合体およびその使用 | |
| JP7446341B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| KR20230133316A (ko) | 항체-약물 접합체를 위한 이중 절단 에스테르 링커 | |
| RU2418003C2 (ru) | Антиангиогенные соединения | |
| CN120731092A (zh) | 用于靶向肿瘤相关巨噬细胞的组合物和方法 | |
| RU2011127520A (ru) | Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r) |